Advanced Miniature In-Line Blood Gas Analyzer Launched in Europe
|
By LabMedica International staff writers Posted on 31 Mar 2015 |

Image: The miniature Proxima Sensor is integrated into a patient’s arterial line to be used for directly monitoring blood gases and electrolytes over a 72 hour period as many times as required (Photo courtesy of Sphere Medical).

Image: The new Proxima in-line patient-dedicated point-of-care blood gas analyzer incorporates Proxima Sensor (in foreground) and dedicated bedside monitor (Photo courtesy of Sphere Medical).
A CE-marked patient-dedicated system, presented at ISICEM 2015, delivers point-of-care testing (POCT) by enabling critical care staff to obtain rapid and frequent laboratory-accurate arterial blood gas measurements without leaving the patient’s bedside, facilitating effective and timely clinical decisions.
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Sphere Medical (Cambridge, UK) presented its Proxima System at the 35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015; Brussels, Belgium, March 17-20, 2015) for launch in mainland Europe. Proxima revolutionizes conventional POCT as it is attached directly to the patient through their arterial line. The miniature Proxima Sensor, containing a range of biological sensors, sits in series in the arterial line with the blood pressure transducer. For the first time, blood gas results can be delivered, like blood pressure results, within the patient’s bed space.
Proxima is simple to use, enables closed blood sampling, and is operated via the touch-screen interface of its dedicated bedside monitor. Blood is withdrawn from the patient directly into the Proxima Sensor and a panel of analytes is measured. All blood is returned to the patient – promoting blood conservation and reducing the possibility of hospital acquired anemia and subsequent transfusions. The disposable sensor can be used for monitoring blood gases and electrolytes over a 72 hour period as many times as required.
Proxima has been fully evaluated and validated in a clinical setting. A recent observational method comparison study at Queen Elizabeth Hospital (Birmingham, UK) showed excellent agreement between Proxima and hospital standard benchtop blood gas analyzers, measuring various parameters of intensive care unit (ICU) patients with a range of clinical conditions, including trauma, head injury, post-surgical recovery, and sepsis.
Dr. Tom Clutton-Brock, senior lecturer, Anaesthesia and Intensive Care Medicine, University Hospital Birmingham, said, “Rapid return of data and swift response to changing blood gases is as essential in-patient care as the continual measurement of blood pressure. Fast feedback and response could have a real impact on efficiently stabilizing patients or weaning them from mechanical ventilation.” At ISICEM 2015 Dr. Clutton-Brock presented on “Bedside Blood Analysis,” discussing how frequent measurement of arterial blood samples is a key component in the effective management of critical care patients, particularly those who are unstable. At a poster session, Dr. Clutton-Brock and Dr. Jess Fox (Sphere Medical) discussed the excellent evaluation results of the Queen Elizabeth Hospital study.
Related Links:
Sphere Medical
35th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2015)
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Molecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







